Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [4]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-95717 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- KIAA1429 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: FMRQILNSDT IGCCGDDNGL MEVEGAHTSR TMSINAAELK QLLQSKEESP ENLFLELEKL VLEHSKDDDN LDSLLDSVVG LKQMLESSGD PLPLSDQDVE PVLSAPESLQ NLFNNRTAYV LADVMDDQLK SMWFTPFQAE EIDTDLDLVK VDLIELSEKC CSDFDLHSEL ERSFLSEPSS PGRTKTTKGF KLGKHKHETF ITSSGKSEYI EPAKRAHVVP PPRGRGRGGF GQGIRPHDIF RQRKQNTSRP PSMHVDDFVA AESKEVVPQD GIPPPKRPLK VSQKISSRGG FSGNRGGRGA F; Positive Samples: K-562, COS7, HeLa, PC-3
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 2.45 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references m(6)A methyltransferase KIAA1429 acts as an oncogenic factor in colorectal cancer by regulating SIRT1 in an m(6)A-dependent manner.
N(6)-methyladenosine (m(6)A) methyltransferase KIAA1429 accelerates the gefitinib resistance of non-small-cell lung cancer.
Zhou Y, Pei Z, Maimaiti A, Zheng L, Zhu Z, Tian M, Zhou Z, Tan F, Pei Q, Li Y, Liu W
Cell death discovery 2022 Feb 25;8(1):83
Cell death discovery 2022 Feb 25;8(1):83
N(6)-methyladenosine (m(6)A) methyltransferase KIAA1429 accelerates the gefitinib resistance of non-small-cell lung cancer.
Tang J, Han T, Tong W, Zhao J, Wang W
Cell death discovery 2021 May 17;7(1):108
Cell death discovery 2021 May 17;7(1):108
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot analysis of KIAA1429 in extracts of various cell lines using KIAA1429 Polyclonal Antibody (Product # PA5-95717) at a dilution of 1:1000. A HRP Goat Anti-Rabbit IgG (H+L) secondary antibody was used at a dilution of 1:10,000. Lysates/proteins: 25 µg per lane. Blocking buffer: 3% nonfat dry milk in TBST.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of KIAA1429 in paraffin-embedded rat brain using KIAA1429 Polyclonal Antibody (Product # PA5-95717) at a dilution of 1:100.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of KIAA1429 in paraffin-embedded human thyroid cancer using KIAA1429 Polyclonal Antibody (Product # PA5-95717) at a dilution of 1:100.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of KIAA1429 in paraffin-embedded human placenta using KIAA1429 Polyclonal Antibody (Product # PA5-95717) at a dilution of 1:100.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of KIAA1429 in paraffin-embedded mouse brain using KIAA1429 Polyclonal Antibody (Product # PA5-95717) at a dilution of 1:100.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 KIAA1429 promoted the proliferation and gefitinib resistance of NSCLC cells. A Short-hairpin RNA (shRNA) and overexpression plasmids were transfected in gefitinib-resistant NSCLC cells (PC9-GR) to construct the silencing and overexpression of KIAA1429. RT-qPCR was performed to detect KIAA1429 mRNA. B Western blot analysis detected the KIAA1429 protein level after silencing or overexpression plasmid transfection. C Wound-healing analysis detected the migrative ability of PC9-GR cells with KIAA1429 silencing or overexpression. D Gefitinib-resistant analysis was performed to detect the IC 50 value (gefitinib concentration causing 50% absorbance decreasing). Bar graphs indicate the means +- SD. * P < 0.05, ** P < 0.01.
